Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that it has entered into a distribution agreement with Imagilin Technology LLC, a U.S.-based veterinary pharmaceutical company to distribute MitoHorseTM, an equine probiotic.
Probiotics work by ensuring a proper balance of good bacteria in the body to enable the absorption of food and nutrients so that the intestines are not overrun with toxins and waste. With a balanced intestinal system, the body is better able to fight illness and inflammation and help prevent the onset of disease (Lin et al, 2009).
MitoHorse™ is a special formula of two beneficial microorganisms, Pediococcus acidilactici, and Saccharomyces boulardii. Both microorganisms are naturally found in animal and human intestines. The formula is designed for the long GI tracts of horses and ponies. When horses and ponies are under stress from environmental changes, they often experience digestive disorders and have weakened immune systems. Experimental studies have demonstrated that horses and ponies fed with MitoHorse™ suffer from fewer stress-related digestive discomforts (Wilson, DA, 2012).
“This product is a welcome addition to the U.S. product portfolio, complementing our existing line of equine feed supplements and the recently introduced Gastrafate®, a GI mucosal protectant that promotes self-healing of equine gastric ulcer syndrome,” said Mr. Andrew Grant, President of Bioniche Animal Health (global).